NCT03467113View on ClinicalTrials.gov

A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 19, 2018

Primary Completion Date

June 24, 2020

Study Completion Date

June 24, 2020

Conditions

Dravet SyndromeLennox Gastaut Syndrome

Interventions

DRUG

ZX008 0.2 to 0.8 mg/kg/day

ZX008 drug is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free.

DRUG

Cannabidiol

Trial Locations (2)

30328

PANDA Neurology/CIRCA, Atlanta

98405

MultiCare Institute for Research & Innovation, Tacoma

All Listed Sponsors

lead

Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.

INDUSTRY

NCT03467113 - A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol | Biotech Hunter | Biotech Hunter